ImmunoGen (NASDAQ:IMGN) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Volatility and Risk
ImmunoGen has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
Profitability
This table compares ImmunoGen and Aeglea BioTherapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| ImmunoGen | -77.65% | N/A | -26.98% |
| Aeglea BioTherapeutics | N/A | -81.42% | -66.88% |
Institutional and Insider Ownership
73.0% of ImmunoGen shares are owned by institutional investors. Comparatively, 80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 3.8% of ImmunoGen shares are owned by insiders. Comparatively, 13.7% of Aeglea BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares ImmunoGen and Aeglea BioTherapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| ImmunoGen | $82.27 million | 18.26 | $-104,130,000.00 | ($0.70) | -10.74 |
| Aeglea BioTherapeutics | $3.89 million | 100.85 | $-78,250,000.00 | ($2.45) | -3.33 |
Aeglea BioTherapeutics has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for ImmunoGen and Aeglea BioTherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| ImmunoGen | 0 | 3 | 4 | 0 | 2.57 |
| Aeglea BioTherapeutics | 0 | 0 | 4 | 0 | 3.00 |
ImmunoGen currently has a consensus target price of $10.10, indicating a potential upside of 34.31%. Aeglea BioTherapeutics has a consensus target price of $12.6667, indicating a potential upside of 55.04%. Given Aeglea BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aeglea BioTherapeutics is more favorable than ImmunoGen.
Summary
Aeglea BioTherapeutics beats ImmunoGen on 9 of the 13 factors compared between the two stocks.
